Article | Published:

Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36

Nature Structural & Molecular Biology volume 18, pages 977983 (2011) | Download Citation

Abstract

Several lines of recent evidence support a role for chromatin in splicing regulation. Here, we show that splicing can also contribute to histone modification, which implies bidirectional communication between epigenetic mechanisms and RNA processing. Genome-wide analysis of histone methylation in human cell lines and mouse primary T cells reveals that intron-containing genes are preferentially marked with histone H3 Lys36 trimethylation (H3K36me3) relative to intronless genes. In intron-containing genes, H3K36me3 marking is proportional to transcriptional activity, whereas in intronless genes, H3K36me3 is always detected at much lower levels. Furthermore, splicing inhibition impairs recruitment of H3K36 methyltransferase HYPB (also known as Setd2) and reduces H3K36me3, whereas splicing activation has the opposite effect. Moreover, the increase of H3K36me3 correlates with the length of the first intron, consistent with the view that splicing enhances H3 methylation. We propose that splicing is mechanistically coupled to recruitment of HYPB/Setd2 to elongating RNA polymerase II.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

GenBank/EMBL/DDBJ

References

  1. 1.

    et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953 (2004).

  2. 2.

    & Dynamic regulation of histone lysine methylation by demethylases. Mol. Cell 25, 1–14 (2007).

  3. 3.

    , & Association of the histone methyltransferase Set2 with RNA polymerase II plays a role in transcription elongation. J. Biol. Chem. 277, 49383–49388 (2002).

  4. 4.

    , , , & The Set2 histone methyltransferase functions through the phosphorylated carboxyl-terminal domain of RNA polymerase II. J. Biol. Chem. 278, 8897–8903 (2003).

  5. 5.

    et al. Phosphorylation of RNA polymerase II CTD regulates H3 methylation in yeast. Genes Dev. 17, 654–663 (2003).

  6. 6.

    et al. Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription. Cell 123, 581–592 (2005).

  7. 7.

    & Eaf3 chromodomain interaction with methylated H3–K36 links histone deacetylation to Pol II elongation. Mol. Cell 20, 971–978 (2005).

  8. 8.

    et al. Cotranscriptional set2 methylation of histone H3 lysine 36 recruits a repressive Rpd3 complex. Cell 123, 593–605 (2005).

  9. 9.

    et al. Combined action of PHD and chromo domains directs the Rpd3S HDAC to transcribed chromatin. Science 316, 1050–1054 (2007).

  10. 10.

    et al. Infrequently transcribed long genes depend on the Set2/Rpd3S pathway for accurate transcription. Genes Dev. 21, 1422–1430 (2007).

  11. 11.

    , & Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 27, 406–420 (2008).

  12. 12.

    et al. Differential chromatin marking of introns and expressed exons by H3K36me3. Nat. Genet. 41, 376–381 (2009).

  13. 13.

    , , & Biased chromatin signatures around polyadenylation sites and exons. Mol. Cell 36, 245–254 (2009).

  14. 14.

    et al. Nucleosome positioning as a determinant of exon recognition. Nat. Struct. Mol. Biol. 16, 996–1001 (2009).

  15. 15.

    , & Chromatin organization marks exon-intron structure. Nat. Struct. Mol. Biol. 16, 990–995 (2009).

  16. 16.

    , , , & Nucleosomes are well positioned in exons and carry characteristic histone modifications. Genome Res. 19, 1732–1741 (2009).

  17. 17.

    , , & Reciprocal intronic and exonic histone modification regions in humans. Nat. Struct. Mol. Biol. 17, 1495–1499 (2010).

  18. 18.

    , , , & Epigenetics in alternative pre-mRNA splicing. Cell 144, 16–26 (2011).

  19. 19.

    , , , & Neuronal cell depolarization induces intragenic chromatin modifications affecting NCAM alternative splicing. Proc. Natl. Acad. Sci. USA 106, 4325–4330 (2009).

  20. 20.

    et al. Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat. Struct. Mol. Biol. 16, 717–724 (2009).

  21. 21.

    , & Histone H3 lysine 9 trimethylation and HP1gamma favor inclusion of alternative exons. Nat. Struct. Mol. Biol. 18, 337–344 (2011).

  22. 22.

    et al. Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol. Cell 28, 665–676 (2007).

  23. 23.

    et al. Regulation of alternative splicing by histone modifications. Science 327, 996–1000 (2010).

  24. 24.

    et al. Transcription initiation platforms and GTF recruitment at tissue-specific enhancers and promoters. Nat. Struct. Mol. Biol. published online, doi:10.1038/nsmb.2085 (17 July 2011).

  25. 25.

    , & The role of chromatin during transcription. Cell 128, 707–719 (2007).

  26. 26.

    et al. Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. Mol. Cell. Biol. 22, 1298–1306 (2002).

  27. 27.

    et al. Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes. J. Biol. Chem. 280, 17732–17736 (2005).

  28. 28.

    et al. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 122, 517–527 (2005).

  29. 29.

    , , , & A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130, 77–88 (2007).

  30. 30.

    , , & Distinct promoter dynamics of the basal transcription factor TBP across the yeast genome. Nat. Struct. Mol. Biol. 16, 1043–1048 (2009).

  31. 31.

    et al. c-Myc regulates transcriptional pause release. Cell 141, 432–445 (2010).

  32. 32.

    et al. High-resolution profiling of histone methylations in the human genome. Cell 129, 823–837 (2007).

  33. 33.

    , , & Diversity of human U2AF splicing factors. FEBS J. 273, 4807–4816 (2006).

  34. 34.

    et al. Tissue-specific splicing factor gene expression signatures. Nucleic Acids Res. 36, 4823–4832 (2008).

  35. 35.

    et al. Distinct localization of histone H3 acetylation and H3–K4 methylation to the transcription start sites in the human genome. Proc. Natl. Acad. Sci. USA 101, 7357–7362 (2004).

  36. 36.

    et al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev. 18, 1263–1271 (2004).

  37. 37.

    et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120, 169–181 (2005).

  38. 38.

    , & Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells. Nat. Struct. Mol. Biol. 13, 815–822 (2006).

  39. 39.

    et al. Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. Mol. Cancer Ther. 8, 2308–2318 (2009).

  40. 40.

    & Physical isolation of nascent RNA chains transcribed by RNA polymerase II: evidence for cotranscriptional splicing. Mol. Cell. Biol. 14, 7219–7225 (1994).

  41. 41.

    , & Molecular dissection of mammalian RNA polymerase II transcriptional termination. Mol. Cell 29, 600–610 (2008).

  42. 42.

    , & Exon tethering in transcription by RNA polymerase II. Mol. Cell 21, 849–859 (2006).

  43. 43.

    & Co-transcriptional splicing of constitutive and alternative exons. RNA 15, 1896–1908 (2009).

  44. 44.

    et al. The in vivo kinetics of RNA polymerase II elongation during co-transcriptional splicing. PLoS Biol. 9, e1000573 (2011).

  45. 45.

    et al. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. J. Biol. Chem. 280, 35261–35271 (2005).

  46. 46.

    , & Coupling of signal transduction to alternative pre-mRNA splicing by a composite splice regulator. EMBO J. 17, 2904–2913 (1998).

  47. 47.

    , & The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat. Struct. Mol. Biol. 13, 22–29 (2006).

  48. 48.

    et al. A novel domain in Set2 mediates RNA polymerase II interaction and couples histone H3 K36 methylation with transcript elongation. Mol. Cell. Biol. 25, 3305–3316 (2005).

  49. 49.

    et al. Solution structure of the Set2-Rpb1 interacting domain of human Set2 and its interaction with the hyperphosphorylated C-terminal domain of Rpb1. Proc. Natl. Acad. Sci. USA 102, 17636–17641 (2005).

  50. 50.

    , , , & Structure and carboxyl-terminal domain (CTD) binding of the Set2 SRI domain that couples histone H3 Lys36 methylation to transcription. J. Biol. Chem. 281, 13–15 (2006).

  51. 51.

    , & Defining mechanisms that regulate RNA polymerase II transcription in vivo. Nature 461, 186–192 (2009).

  52. 52.

    , & Splicing, transcription, and chromatin: a menage a trois. Curr. Opin. Genet. Dev. 18, 145–151 (2008).

  53. 53.

    & Terminal differentiation of murine erythroleukemia cells: physical stabilization of end-stage cells. J. Cell Biol. 93, 390–394 (1982).

  54. 54.

    et al. Transcribing RNA polymerase II is phosphorylated at CTD residue serine-7. Science 318, 1780–1782 (2007).

  55. 55.

    et al. The UCSC Genome Browser database: update 2010. Nucleic Acids Res. 38, D613–D619 (2010).

  56. 56.

    , , & affy–analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307–315 (2004).

  57. 57.

    et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 (2001).

  58. 58.

    , , & A link between nuclear RNA surveillance, the human exosome and RNA polymerase II transcriptional termination. Nucleic Acids Res. 38, 8015–8026 (2010).

  59. 59.

    , , & Fast chromatin immunoprecipitation assay. Nucleic Acids Res. 34, e2 (2006).

Download references

Acknowledgements

We are grateful to K. Koide (University of Pittsburgh), for kindly providing the meayamycin used in this study. We are also thankful to S. Marinho (Faculdade de Medicina, Universidade de Lisboa) for technical assistance. This work was supported by grants from Fundação para a Ciência e Tecnologia (PTDC-BIA-BCM-101575-2008 to M.C.-F. and PTDC-BIA-BCM-111451-2009 to S.F.deA.) and the European Commission (MRTN-CT-2006-035733 to M.C.-F. and P.F.). S.F.deA. and A.R.G. are supported by fellowships from Fundação para a Ciência e Tecnologia (SFRH-BPD-34679-2007 and SFRH-BPD-62911-2009). Work in the P.F. laboratory is supported by institutional grants from Institut National de la Santé et de la Recherche Médicale (INSERM) and Centre National de la Recherche Scientifique (CNRS), and by specific grants from Fondation Princesse Grace de Monaco, the Agence Nationale de la Recherche (ANR), the Institut National du Cancer (INCa) and the Commission of the European Communities. F.K. was supported by a Marie Curie research training fellowship (MRTN-CT-2006-035733); and is now supported by Association pour la Recherche sur le Cancer (ARC). R.F. was supported by Marseille-Nice Genopole; and is now supported by a grant from CNRS.

Author information

Affiliations

  1. Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.

    • Sérgio Fernandes de Almeida
    • , Ana Rita Grosso
    • , Sílvia Carvalho
    • , Jorge Andrade
    • , Helena Levezinho
    •  & Maria Carmo-Fonseca
  2. Centre d'Immunologie de Marseille-Luminy, Centre National de la Recherche Scientifique (CNRS) UMR6102, Institut National de la Santé et de la Recherche Médicale (INSERM), U631, Université de la Méditerranée, Marseille, France.

    • Frederic Koch
    • , Romain Fenouil
    • , Jean-Christophe Andrau
    •  & Pierre Ferrier
  3. Centre Nacional D'Anàlisi Genòmica, Parc Cientific de Barcelona, Barcelona, Spain.

    • Marta Gut
    •  & Ivo Gut
  4. Department of Molecular Epigenetics, Helmholtz Center Munich, Center of Integrated Protein Science, Munich, Germany.

    • Dirk Eick

Authors

  1. Search for Sérgio Fernandes de Almeida in:

  2. Search for Ana Rita Grosso in:

  3. Search for Frederic Koch in:

  4. Search for Romain Fenouil in:

  5. Search for Sílvia Carvalho in:

  6. Search for Jorge Andrade in:

  7. Search for Helena Levezinho in:

  8. Search for Marta Gut in:

  9. Search for Dirk Eick in:

  10. Search for Ivo Gut in:

  11. Search for Jean-Christophe Andrau in:

  12. Search for Pierre Ferrier in:

  13. Search for Maria Carmo-Fonseca in:

Contributions

S.F.deA. and M.C.-F. conceived the project and designed the experiments. S.F.deA., S.C., J.A., H.L. conducted and analyzed the wet-lab experiments. F.K., I.G., J.-C.A. and P.F. conceived the framework of the ChIP-seq studies. F.K. and J.-C.A. designed the ChIP-seq experiments. D.E. produced and provided the Ser2P and Ser5P Pol II antibodies. R.F. and F.K. carried out the bioinformatics preprocessing of ChIP-seq data. ChIP-seq and RNA-seq preprocessing materials were prepared by F.K.. M.G. and I.G. conducted all ChIP-seq– and RNA-sequencing experiments. A.R.G carried out the bioinformatic analysis of microarray, ChIP-seq and RNA-seq data. S.F.deA., A.R.G. and M.C.-F. wrote the manuscript. All authors reviewed the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Jean-Christophe Andrau or Pierre Ferrier or Maria Carmo-Fonseca.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–6, Supplementary Tables 1 and 2 and Supplementary Methods

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nsmb.2123

Further reading